

SCRI Trials and Trial Regimen Updates

The following updates were completed between January 21 - February 19, 2026. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.

For questions about these trials and regimens, please contact SCRiKMEMRedits@McKesson.com.

New Builds Completed

Study Number	Notes for New Build
25003	USOR 25003 GU 271 Phase 3 Cohort A Saruparib or Placebo + ADT Q28D - v2.0 10APR2025 USOR 25003 GU 271 Phase 3 Cohort B Saruparib or Placebo + Abiraterone + ADT Q28D - v2.0 10APR2025
24316	USOR 24316 CH 04 Phase 1 Pirtobrutinib Q28D 02Oct2024
24303	USOR 24303 GYN 150 Phase 3 Arm A AZD8205 Q21D - v1.0 05FEB2025 USOR 24303 GYN 150 Phase 3 Arm B Doxorubicin Q21D - v1.0 05FEB2025 USOR 24303 GYN 150 Phase 3 Arm B Paclitaxel Q28D - v1.0 05FEB2025
25155	USOR 25155 GI 429 Phase 2 Pumitamig or Nivolumab + FOLFOX Q14D - 27Oct2025
24154	USOR 24154 GI 395 Phase 3 Arm E1 T-DXd + 5-FU Q21D - v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm E1 T-DXd + Capecitabine Q21D - v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm E2 Trastuzumab + Cisplatin + 5-FU Q2D - v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm E2 Trastuzumab + Oxaliplatin + Capecitabine Q21D - v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm M1 T-DXd + Pembrolizumab + 5-FU Q21D - v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm M1 T-DXd + Pembrolizumab + Capecitabine Q21D - v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm M2 Pembrolizumab + Trastuzumab + Cisplatin + 5-FU Q2D - v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm M2 Pembrolizumab + Trastuzumab + Oxaliplatin + Capecitabine Q21D - v2.0 03APR2025
25031	USOR 25031 LUN 615 Phase 3 Durvalumab + Carboplatin + Etoposide Q21D - 07FEB2025 USOR 25031 LUN 615 Phase 3 Durvalumab Q28D - 07FEB2025 USOR 25031 LUN 615 Phase 3 Tarlatamab + Durvalumab + Carboplatin + Etoposide Q21D - 07FEB2025 USOR 25031 LUN 615 Phase 3 Tarlatamab + Durvalumab Q28D - 07FEB2025
24332	USOR 24332 GU 269 Phase 2 Arm 1 JSB462 + AAA617 Q42D USOR 24332 GU 269 Phase 2 Arm 2 JSB462 + AAA617 Q42D USOR 24332 GU 269 Phase 2 Arm 3 AAA617 Q42D USOR 24332 GU 269 Phase 2 JSB462 Q14D (randomization period)
24187	USOR 24187 GYN 154 Phase 3 Part 2 Arm 1 Sacituzumab Tirumotecan +/- Bevacizumab Q42D - 01APR2025 USOR 24187 GYN 154 Phase 3 Part 2 Arm 2 Bevacizumab Q42D - 01APR2025

Study Number	Notes for New Build
25035	USOR 25035 LUN 616 Phase 3 Dato-DXd Q21D - v1.0 26FEB2025 USOR 25035 LUN 616 Phase 3 Docetaxel Q21D - v1.0 26FEB2025
25073	USOR 25073 GU 283 Phase 3 Part 2 Group A 177Lu-TLX591 + SOC D1,15 (IP only) - v6.0 25FEB2025 USOR 25073 GU 283 Phase 3 Part 2 Group A or B ARPI Q30D - v6.0 25FEB2025 USOR 25073 GU 283 Phase 3 Part 2 Group A or B Docetaxel Q21D - v6.0 25FEB2025
25099	USOR 25099 LYM 219 Phase 2 Bridging Therapy (Placeholder) - 24JUN2025 USOR 25099 LYM 219 Phase 2 JNJ-90014496 D1 - 24JUN2025 USOR 25099 LYM 219 Phase 2 Lymphodepletion Fludarabine + Cyclophosphamide D-5,-4,-3 - 24JUN2025
25090	USOR 25090 LUN 629 Phase 3 Lurbinectedin Q21D - v2.0 03Sep2025 USOR 25090 LUN 629 Phase 3 Tarlatamab D1,8,15 fb D1,15 Q28D - v2.0 03Sep2025 USOR 25090 LUN 629 Phase 3 Topotecan IV Q21D - v2.0 03Sep2025 USOR 25090 LUN 629 Phase 3 Topotecan PO Q21D - v2.0 03Sep2025 USOR 25090 LUN 629 Phase 3 ZL-1310 Q21D - v2.0 03Sep2025
RM 1324 MCCR	RM 1324 Phase 1 CR-001 Q28D - 31Dec2025
25044	USOR 25044 GU 278 Phase 3 Abiraterone Q28D - 07MAY2025 USOR 25044 GU 278 Phase 3 Cabazitaxel Q21D - 07MAY2025 USOR 25044 GU 278 Phase 3 Docetaxel Q21D - 07MAY2025 USOR 25044 GU 278 Phase 3 Xaluritamig + Abiraterone Q28D - 07MAY2025
24268	USOR 24268 CLL 66 Phase 2 NX-5948 Q28D - 18Nov2025
RM 1306 MCCR	RM 1306 Phase 1a/1b Part A NRM-823 Q21D - v2.0 02SEP2025

Updated Reference Information

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
25049	PM v2.0; 15th January 2026	N/A	N/A	Update drug; instructions
25042	Version 2.0; 10 June 2025	N/A	Regimen comments; Admin	Update drug; Instructions, frequency

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
24196	Version 4.0; 04 Sept 2025	N/A	Regimen comments; Premedication	N/A
24179	Version 4.0; 06 November 2025	N/A	N/A	Update drug; instructions
24093	PA v4.0; 10 August 2025	N/A	Regimen comments; admin, prophylaxis	Update drug; instructions
23252	Version 4.0; 04 July 2025	N/A	Regimen comments; Prophylaxis, Observation	Update Drug; instructions
23239	PA v7.0; 21 July 2025	N/A	Regimen comments; Admin	Update drug; instructions, name
23236	PA v3.0; 30 July 2025	N/A	Regimen comments; admin	Update drug; instructions, premedication
22326	Version 4.0; 10 July 2025	N/A	Regimen comments; admin	Update drug; Premedication
22325	PM v7.0; 13th January 2026	N/A	N/A	Update drug; instructions
22298	PM v5.0; 18 December 2025	N/A	N/A	Update drug; dose, form
22297	PA v4.0; 22 April 2025	N/A	Regimen comments; admin	Update drug; premedication
22037	Version 11.0; 12 August 2025	N/A	Regimen comments; Admin	Update drug; instructions, premedication
23294	IP Handling Instructions v5.0; 23rd January 2026	N/A	N/A	Update drug; instructions

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
24144	Version 7.0; 15th October 2025	N/A	N/A	Update drug; instructions, name. Added Drug
24098	Version 1.0; 06 August 2025	N/A	Regimen comments; admin, premedication	Update drug; premedication procurement
25086	Version 6.0; 16 October 2025	N/A	Regimen comments; admin, observation	Update drug; instructions, New Arm(s)
25086	PM v6.0; 18th December 2025	N/A	N/A	Update drug; instructions
24325	Adding G-CSF per process updated	N/A	N/A	Added Drug
24139	PCL; 11 November 2025	N/A	N/A	Update drug; instructions
24025	Version 3.0, 06NOV2024	N/A	N/A	Update drug; instructions
24139	Version 8.0; 22 Sept 2025	N/A	Regimen comments; admin	Update drug; instructions, procurement
24144	Version 7.0, 15 October 2025	N/A	N/A	New Arm(s)